WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

William Garrett Gray net worth and biography

William Gray Biography and Net Worth

CFO of Checkpoint Therapeutics

William Garrett Gray serves as Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary of the Company. Mr. Gray has served as our Vice President, Finance and Accounting since February 2016, as our Principal Financial Officer since December 2016, and as our Corporate Secretary since January 2018. Mr. Gray joined us from Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, which he joined in 2013, and where he most recently served as Corporate Controller, helping grow the finance and accounting department during Keryx’s transition from a development-stage company to a fully integrated commercial organization. Prior to joining Keryx, Mr. Gray began his professional career with Deloitte & Touche, LLP, where he served as a senior auditor. Mr. Gray has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New York.

What is William Garrett Gray's net worth?: The estimated net worth of William Garrett Gray is at least $3.87 million as of December 18th, 2024. Mr. Gray owns 1,032,754 shares of Checkpoint Therapeutics stock worth more than $3,872,828 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Gray may own. Additionally, Mr. Gray receives an annual salary of $409,120.00 as CFO at Checkpoint Therapeutics. Learn More about William Garrett Gray's net worth.
How old is William Garrett Gray?: Mr. Gray is currently 37 years old. There are 1 older executives and no younger executives at Checkpoint Therapeutics. The oldest executive at Checkpoint Therapeutics is Mr. James F. Oliviero III, C.F.A., President, CEO & Director, who is 48 years old. Learn More on William Garrett Gray's age.
What is William Garrett Gray's salary?: As the CFO of Checkpoint Therapeutics, Inc., Mr. Gray earns $409,120.00 per year. The highest earning executive at Checkpoint Therapeutics is Mr. James F. Oliviero III, C.F.A., President, CEO & Director, who commands a salary of $921,590.00 per year. Learn More on William Garrett Gray's salary.
How do I contact William Garrett Gray?: The corporate mailing address for Mr. Gray and other Checkpoint Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. Checkpoint Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on William Garrett Gray's contact information.
Has William Garrett Gray been buying or selling shares of Checkpoint Therapeutics?: Over the course of the past ninety days, William Garrett Gray has sold $1,076,412.32 in Checkpoint Therapeutics stock. Most recently, William Garrett Gray sold 268,432 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a transaction totalling $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares of the company's stock, valued at $4,141,343.54. Learn More on William Garrett Gray's trading history.
Are insiders buying or selling shares of Checkpoint Therapeutics?: In the last year, insiders at the sold shares 8 times. They sold a total of 550,254 shares worth more than $1,946,395.84. The most recent insider tranaction occured on December, 19th when CEO James F Oliviero III sold 220,230 shares worth more than $744,377.40. Insiders at Checkpoint Therapeutics own 2.1% of the company. Learn More about insider trades at Checkpoint Therapeutics.
Information on this page was last updated on 12/19/2024.

William Garrett Gray Insider Trading History at Checkpoint Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2024	Sell	268,432	$4.01	$1,076,412.32	1,032,754
6/26/2024	Sell	13,038	$2.06	$26,858.28	672,186
2/28/2024	Sell	2,035	$2.07	$4,212.45	145,224
2/1/2024	Sell	4,115	$1.95	$8,024.25	147,259
3/2/2023	Sell	3,591	$5.00	$17,955.00	51,374
2/27/2023	Sell	1,914	$4.66	$8,919.24	47,465
2/1/2023	Sell	3,154	$4.79	$15,107.66	49,379
1/10/2023	Sell	1,858	$6.75	$12,541.50	52,533
3/10/2022	Sell	3,819	$18.90	$72,179.10
2/1/2022	Sell	3,706	$25.10	$93,020.60
2/4/2021	Sell	2,632	$36.60	$96,331.20
12/22/2020	Sell	240	$27.90	$6,696.00

William Garrett Gray Buying and Selling Activity at Checkpoint Therapeutics

Checkpoint Therapeutics Company Overview

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Today's Range

Now: $3.75

$3.33

$3.76

50 Day Range

MA: $3.59

$2.54

$4.39

2 Week Range

Now: $3.75

$1.38

$4.50

Volume

2,234,921 shs

Average Volume

675,598 shs

Market Capitalization

$183.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad